Biogen (BIIB) shares down 3% following Eli Lilly & Co. (LLY) failure of solanezumab data for Alzheimer's
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Biogen (BIIB) PT Lowered to $355 at Leerink Partners on Reduced Aducanumab Probability of Success
November 25, 2016 8:52 AM ESTLeerink Partners analyst Geoffrey Porges reduced Aducanumab probability of success and cut his price target on Biogen (NASDAQ: BIIB) price target of $355.00 (from $365.00) after Lilly announced on Wednesday that the EXPEDITION 3 study of solanezumab (sola) in mild Alzheimer's patients did not meet its primary or secondary... More
Sola News Negative for Biogen (BIIB) as Latest in Numerous Failures for the Mechanism - Baird
November 23, 2016 10:40 AM ESTBaird analyst Brian Skorney weighed in on Biogen (NASDAQ: BIIB), saying Eli Lilly's Solanezumab failure is a negative for the company.,
Skorney commented, "Lilly's registrational EXPEDITION 3 trial for solanezumab in mild Alzheimer's patients failed. Though some secondary endpoints favored sola, Lilly's admission that... More
Mizuho Sees Near-Term Trading Opportunity in Biogen (BIIB) Amid Weakness
November 23, 2016 9:48 AM ESTMizuho analyst Salim Syed weighed in on Biogen (NASDAQ: BIIB) after Eli Lilly announced this morning that its Alzheimer's drug, Solanezumab Phase 3 study has failed and it will not pursue approval which has implications to Biogen's Aducanumab.
Syed commented, "While we are... More
Sola Failure Decreases Value of Biogen's (BIIB) Aducanumab - BMO Capital
November 23, 2016 9:27 AM ESTBMO Capital analyst M. Ian Somaiya weighed in on Biogen (NASDAQ: BIIB) with shares down on Eli Lilly's solanezumab's failure. The analyst said the news decreases the value of aducanumab's.
Somaiya commented, "We expect BIIB shares to trade down on solanezumab's failure, as we... More
Eli Lilly Sola Failure is a 'Serious Blow' to Biogen (BIIB) and Others in AD Field - Leerink
November 23, 2016 7:57 AM ESTLeerink Partners analyst Geoffrey Porges weighed in on Biogen (NASDAQ: BIIB) after Eli Lilly (NYSE: LLY) announced that the solanezumab (sola) phase III trial in patients with mild Alzheimers disease failed to meet statistical significance on the primary endpoint and only... More
